Gpi Spa · MIL:GPI
Gpi Spa — Investor Presentation (June 2023)
31 slides from Gpi Spa's investor presentation, June 2023
Slide 1: Investor Presentation FY22
INVESTOR PRESENTATION FY22 J u n e 2023
Slide 2: Vision, Mission, Values
2 VISION 35 years of experience, History of to be at the forefront of the technological Growth management team with a track record of internal growth and and sustainable transformation of M&As preventive and care processes for healthcare, promoting the well-being of International solutions used by 3
Slide 3: Digital Health: the Solution for the Health Care Market
3 Digital Health: the Solution for the Health Care Market Current environment Digital health solution Effects and streamlining Resources optimization and Shortage of medical staff AUTOMATION impact on average (doctors, nurses) hospitalization Complex and intricate Process facilitation and MANAGEMENT
Slide 4: A History of Steady Growth
4 a History of Revenue FY22 EBITDA FY22 Steady € 360.2 M € 54.2 M Growth % on adj. Revenue 17.4% 16.7% 16.4% 16.0% 16.0% 15.2% 15.1% 386.1 14.8% 360.2 61.8 326.9 271.0 54.2 49.8 M&A deals 40.2 ca. 7k € 200 M Employees in the last 6 years 2020 2021 2022 2022 2020 2021 2022 2022 Pro Forma Pro Forma 3,
Slide 5: Supply Lines FY22
5 Supply Lines FY22 Software Care € 140.6 M Revenue € 166.5 M Revenue € 137.6 M EBITDA € 166.5 M EBITDA 91% Retention 95% Retention 41% Recurring fees 93% Recurring fees 1-3 years Average contract length 4-6 years Average contract length Modular and integrated information systems: Supporting the Nat
Slide 6: Geographic Footprint and Customer Base
6 Geographic Footprint Customer Base Italy: the entire offering Health Public 80.0% DACH: Blood, HIS, Virtual Care (VC), Automation RoW: Blood, Automation, Virtual Care +24.4% • Healthcare Authorities • Hospitals (mainly in Europe & the Americas) YoY • Public providers (in-house) • Regions, Province
Slide 7: Highlights FY22
7 Highlights FY22 Entering the Japanese market with pharmacy robots A year of extraordinary transactions and investments for international growth and New contracts in Greece, Estonia, Saudi Arabia company consolidation (whole Countries ~ € 14 M ) Consip Framework Agreement “1” EMR & Telemed: the con
Slide 8: P&L: Strong Growth in FY22
8 P&L: Strong Growth in FY22 Revenue € 360.2 M +10.2% | 8.7% organic €M FY22 FY22 FY21 (pro forma €386.1 +18.1%) pro forma • SW € 140.5 M +19.5% • Care € 168.8 M +1.6% Revenue & other income 386.1 360.2 326.9 • Other € 50.8 M +18.0% Adjusted Revenue1 355.6 329.7 298.1 EBITDA € 54.2 M | 16.4% on adj.
Slide 9: Revenue Breakdown by SBA (€M)
9 Revenue Breakdown by SBA (€M) • Software reported +19.5% thanks to Consip Framework Agreement Tenders for digitizing health care. 386.1 360.2 13.6 19.7 The acquisition of Tesi flows entirely into SBA Software, 13.6 which would exceed € 166 M in revenue, consolidating its 326.9 17.5 19.7 11.3 17.5
Slide 10: EBITDA Breakdown by SBA (€M)
10 EBITDA Breakdown by SBA (€M) • Software increased its EBITDA by € 4.6 M, which 17.4% 16.7% further grew by € 7.6 M when added up the pro 16.4% 16.0% forma consolidated EBITDA from Tesi. 15.2% 17.5 15.1% 61.8 • Care profitability slightly shrank because of higher 4.5 corporate costs impacting the
Slide 11: Revenue Adj. and EBITDA by SBA FY22 (€ M)
11 Revenue Adj. and EBITDA by SBA FY22 (€ M) • Software reported an increase both in Revenue and EBITDA with a slight reduction in margin, due to an increase in the incidence of corporate costs and of the cost of services. The pro forma brings the marginality of Software up to € 45 M and an EBITDA 7
Slide 12: Financial Highlights FY22
12 Financial Highlights FY22 CERVED Rating A3.1 equivalent to A- S&P, A3 Moody’s, A-1 Fitch €M Fixed assets FY22 FY21 investments (Tesi and VC “service tech sub-fund” included) investments in new innovative products and solutions Fixed assets 259.7 166.8 Net Working Capital (+) trade receivables € 4
Slide 13: NFI Bridge
13 NFI Bridge TESI, IOP, ESAKON, + € 137.5 M net of cash Non-cash CapitaI acquired adjustments Increase and recovery net of costs Venture of payables Capital for - € 9.2 M extraordinary o/w R&D Dividend cash out for operations € 14.2 M extraordinary (NFI-neutral) operations
Slide 14: Competitive Ranking – Italian Top Players
14 Competitive Ranking – Italian Top Players Software BPO AtC (Business Process Outsourcing) Company Focus on Addressable market Company HC ca. € 1 bn ✓ 5 Top Players ✓ Through 35%1 ~50% dedicated healthcare division Reply’s subsidiary Through GPI has a potential reach dedicated healthcare division
Slide 15: Fast Growing Markets of IT Software & Services in Health Care
15 Fast Growing Markets of IT Software & Services Potential effects of NRRP on in Health Care the Italian digital healthcare market € 5.8 bn 2021-2026 Funds dedicated to the World ($ B) Italy ($ B) digitalization of healthcare of which: +12.7% • € 3.6 bn CAGR 147 22-25 +11.7% for ICT 131 59.1 116 45
Slide 16: Strategic Pillars of the Business Plan 2022 – 2024
16 Strategic Pillars of the Business Plan 2022 – 2024 Values, Mission and Vision 1. 2. 3. 4. Global Leader Interconnected Innovative and Secure B. Structure, Processes and Governance A. Sustainability, Impact, Brand and Reputation
Slide 17: Strategic Pillars of the Business Plan 2022 – 2024
17 Strategic Pillars of the Business Plan 2022 – 2024 • Develop and implement a sustainability plan with particular reference to the social component, in the field of Sustainability, health care, measuring potential impacts through defined metrics (SDG n 3 Good Health UN 2030 Agenda) A Impact, Brand
Slide 18: Significant M&A Track Record
18 Significant M&A Track Record
Slide 19: M&A Guidelines
19 M&A Guidelines Become a Major European Player will keep on investing in software companies both abroad and in Italy to expand its product portfolio Focus on international software companies mainly operating in: Blood Management LIS with an EBITDA margin > 16% Product Portfolio Evolution: Software
Slide 20: Targets 2024
20 Targets 2024 €M 2022 pro forma 2024 Organic Organic REVENUE + 8.7% > 420 mn CAGR 2021-2024 > 8.5% 386 > 500 Organic & inorganic Organic & inorganic + 18.1% > 500 mn CAGR 2021-2024 > 15% EBITDA 16% > 17% Margin
Slide 21: Appendix: Featured Products
Appendix Featured Products
Slide 22: A New Architecture of Integrated Solutions
22 A New Architecture of Integrated Solutions Threshold Values and Alert Structured Interaction with Patients Monitoring Dashboard Proactivity and Care IoT – Sensors – Dedicated Apps Intelligent Cloud Management Dataflow Monitoring Direct Interaction with Patients Technologies for Enabling Disease P
Slide 23: Phoema Features
23 PHOEMA FEATURES Remote consulting by audio-video conference system Imaging (access, sharing and diagnostic assistance) Telemonitoring (24h/7) with advanced Multiparametric medical devices Remote diagnosis 23
Slide 24: Blood Management System
24 Blood Managment ranks 5th on the global market of Blood transfusion sw System Software France USA USA USA Italy USA USA Australia USA Germany USA China China China USA Source: QY Research
Slide 25: Gpi 4 Blood
25 • Gpi 4 Blood Blood Banks DONORS TRASFUSIONS BI MIDDLEWARE (INSTRUMENTS INTERFACES) Tissue Banks TISSUE BANKS BI MIDDLEWARE Human Milk Banks HMB BI MIDDLEWARE Cells Therapy CELLS THERAPY BI MIDDLEWARE Cord Blood Banks CORD BLOOD BI MIDDLEWARE HLA HLA BI MIDDLEWARE Laboratory LIS BI 25 MIDDLEWARE
Slide 26: Vein-to-Vein process
26 Blood Donor Centers Hospitals ‘‘Vein-to-Vein’’ process
Slide 27: A New Concept in Pharmacy Automation
27 A New Concept in Pharmacy Automation RIEDL PHASYS ⚫ The fastest system on the market: 5 m/sec ⚫ Wireless: no cable ⚫ Manages products of various shapes ⚫ Multi Picking ⚫ Fully integrated and tailored ⚫ Positive air pressure ' No more dust '
Slide 28: Forward Thinking: Two Main Strategic Trajectories
28 Forward Thinking: Two Main Strategic Trajectories Population Health Management Models and Detect the demand for care, Virtual Care Build and keep technologies Regression models & clustering (AI) • Telemedicine 1 for the Patient Pathway (PDTA) • IoT and Augmented Telemed connections • Audio Video
Slide 29: Investment Quick Take
29 Investment Quick Take Shareholder structure based on information available to Gpi on June 12th, 2023 Leadership and Uniqueness FM (Manzana Family) 34.3% CDP Equity 46.9% GPI IN THE STOCK MARKET Growth and Visibility Treasury Shares ISIN: IT0005221517 0.3% Ticker: GPI:IM Market 18.4% Price 12 June
Slide 30: IR Contact details
30 IR Contact details Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor.relations@gpi.it Fabrizio Redavid Lorenzo Giollo C. +39 335 1035499 C. +39 340 8223333 fabrizio.redavid@gpi.it lorenzo.giollo@gpi.it
Slide 31: Disclaimer
31 Disclaimer The material in this presentation was prepared by GPI S.p.A. ("GPI” or the “Company”) without any paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be form of independent verification; it is general, basic information about the current busi